PDCD1 and nasopharyngeal carcinoma: Therefore, blocking the PD-1/PD-L1 interaction is believed to substantially increase cellular antitumor activity against NPC cells, as already observed in other malignancies, for example, non-small-cell lung cancer (NSCLC; [13, 14]).